BioInvent at a glance
As of June 30, 2025
Listen to CSO Björn Frendéus at the BioStock event Investing in Life Science - From Seed to Success
September 23, 2025


Redeye interviews CEO Martin Welschof and CMO Andres McAllister about BI-1808 in
T-cell lymphoma
Redeye interviews CEO Martin Welschof and CMO Andres McAllister about BI-1808 in T-cell lymphoma.
Interview with CEO Martin Welschof and CMO Andres McAllister
Interview with CEO Martin Welschof and CMO Andres McAllister on the latest data for BI-1206 in solid tumors
June 11, 2025
Jefferies Global Healthcare Conference, New York

Interview with CEO Martin Welschof and CMO Andres McAllister
May 27, 2025
Interview with CEO Martin Welschof about the Xoma deal
May 27, 2025

BioInvent is in a very attractive position with multiple value drivers
BioInvent has five ongoing clinical programs, where each program has its own individual mechanism of action. In this way, the company is not dependent on the success of one individual program or one single technology. In the Discovery phase, BioInvent applies a stringent process in order to make sure that all of the company’s drug candidates have a smart design and high commercial potential for successful partnering at the optimal time for each project.
The company’s Discovery engine not only generates new drug candidates, it also offers ample opportunity for successful collaborations and partnering.


Stringent portfolio management
All pharmaceutical development is associated with risk. BioInvent manages these risks by a stringent portfolio management, a diversified approach to drug candidates and mechanisms of action, and by targeting a very attractive space in the pharmaceutical landscape. Partnerships within the big pharma community, solid ownership and a strong cash position give BioInvent a solid platform to continue its transformation.
Investor Relations contact
BioInvent strives to provide the financial markets with accurate, consistent and relevant information about the company on a regular basis. In the first instance, IR-related issues should be addressed to the Senior Director Investor Relations.